MedTrace Logo

Letrozole and Misoprostol for Termination of Pregnancy up to 63 Days' Gestation

NCT05207644 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2022-06-15

No results posted yet for this study

Summary

Study to determine if a user-friendly medical abortion regimen using letrozole and misoprostol is safe and acceptable.

Conditions

  • Pregnancy

Interventions

DRUG

30 mg letrozole followed by 800 mcg misoprostol

30 mg letrozole on day 1 followed by 800 mcg misoprostol on day 3

Sponsors & Collaborators

  • Gynuity Health Projects

    lead OTHER

Principal Investigators

  • Tara Shochet, PhD, MPH · Gynuity Health Projects

  • Beverly Winikoff, MD, MPH · Gynuity Health Projects

  • David Turok, MD, MPH · The University of Utah

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-12-09
Primary Completion
2022-04-30
Completion
2022-04-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05207644 on ClinicalTrials.gov